QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 0.0083
-- x --
-- x --
-- - --
$ 0.01 - $ 3.00
31,371
na
na
$ 1.84
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 us-stocks-likely-to-open-lower-after-wednesdays-blip-be-patient-but-be-ready-to-act-says-analyst-as-market-uncertainties-can-create-opportunities

U.S. stock futures fell on Thursday following Wednesday’s relief after a two-day fall. Futures of all four benchmark indices fe...

 cutera-cutr-shares-are-down-45-today-whats-going-on

Cutera shares are trading lower by 48% during Wednesday's session. The company announced a restructuring plan backed by len...

 cutera-files-for-chapter-11-reduces-debt-by-400m-and-secures-65m-in-new-funding

CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today ann...

 cutera-affirms-fy2024-sales-guidance-to-14000m-14500m--vs-est14153m

Cutera (NASDAQ:CUTR) affirms FY2024 sales outlook from $140.00 million-145.00 million to $140.00 million-145.00 million.

 cutera-q3-2024-adj-eps-167-misses-096-estimate-sales-32500m-beat-32086m-estimate

Cutera (NASDAQ:CUTR) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $(0.96) by 7...

 stephens--co-maintains-overweight-on-cutera-lowers-price-target-to-5

Stephens & Co. analyst George Sellers maintains Cutera (NASDAQ:CUTR) with a Overweight and lowers the price target from ...

 piper-sandler-reiterates-neutral-on-cutera-lowers-price-target-to-1

Piper Sandler analyst Matt O'Brien reiterates Cutera (NASDAQ:CUTR) with a Neutral and lowers the price target from $3 to...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION